Semaglutide is a medication primarily used in the management of type 2 diabetes and obesity, offering significant benefits in improving blood sugar control and supporting weight reduction. It belongs to the class of glucagon‑like peptide‑1 (GLP‑1) receptor agonists, which mimic the natural hormone that regulates appetite and insulin secretion. By enhancing insulin release when blood sugar levels are elevated and reducing glucose production in the liver, semaglutide helps maintain more stable glycemic control. Additionally, it slows gastric emptying, which promotes a feeling of fullness and reduces overall food intake, making it effective for weight management in individuals struggling with obesity. Beyond its metabolic effects, semaglutide has shown potential in lowering cardiovascular risks by improving key health markers such as blood pressure and cholesterol levels. Its dual role in addressing both diabetes and obesity makes it a valuable therapeutic option for long‑term health improvement and lifestyle management.